Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Pillars Article: A 39-kDa Protein on Activated Helper T Cells Binds CD40 and Transduces the Signal for Cognate Activation of B Cells. Proc. Natl. Acad. Sci. 1992. 89: 6550-6554.

Noelle RJ, Roy M, Shepherd DM, Stamenkovico I, Ledbetter JA, Aruffo A.

J Immunol. 2016 Dec 1;197(11):4195-4199. No abstract available.

2.

Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease.

Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, Malech HL, Ledbetter JA, Elkon KB, Kaplan MJ.

Nat Med. 2016 Feb;22(2):146-53. doi: 10.1038/nm.4027. Epub 2016 Jan 18.

3.

Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice.

Sun X, Wiedeman A, Agrawal N, Teal TH, Tanaka L, Hudkins KL, Alpers CE, Bolland S, Buechler MB, Hamerman JA, Ledbetter JA, Liggitt D, Elkon KB.

J Immunol. 2013 Mar 15;190(6):2536-43. doi: 10.4049/jimmunol.1202689. Epub 2013 Feb 4.

5.

Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway.

Chaplin JW, Kasahara S, Clark EA, Ledbetter JA.

J Immunol. 2011 Oct 15;187(8):4199-209. doi: 10.4049/jimmunol.1100198. Epub 2011 Sep 14.

6.

Rapid activation of glutamate cysteine ligase following oxidative stress.

Krejsa CM, Franklin CC, White CC, Ledbetter JA, Schieven GL, Kavanagh TJ.

J Biol Chem. 2010 May 21;285(21):16116-24. doi: 10.1074/jbc.M110.116210. Epub 2010 Mar 23.

7.

CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.

Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA.

Clin Cancer Res. 2009 Apr 15;15(8):2739-46. doi: 10.1158/1078-0432.CCR-08-1694. Epub 2009 Apr 7.

8.
9.

How does B cell depletion therapy work, and how can it be improved?

Clark EA, Ledbetter JA.

Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv77-80. Review.

10.

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE.

Cancer Res. 2003 Jul 1;63(13):3695-700.

11.

Expression and characterization of recombinant soluble human CD3 molecules: presentation of antigenic epitopes defined on the native TCR-CD3 complex.

Law CL, Hayden-Ledbetter M, Buckwalter S, McNeill L, Nguyen H, Habecker P, Thorne BA, Dua R, Ledbetter JA.

Int Immunol. 2002 Apr;14(4):389-400.

PMID:
11934875
12.

Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.

Ye Z, Hellström I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellström KE.

Nat Med. 2002 Apr;8(4):343-8.

PMID:
11927939
13.

Cutting edge: CD83 regulates the development of cellular immunity.

Scholler N, Hayden-Ledbetter M, Dahlin A, Hellström I, Hellström KE, Ledbetter JA.

J Immunol. 2002 Mar 15;168(6):2599-602.

14.

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells.

Richter G, Hayden-Ledbetter M, Irgang M, Ledbetter JA, Westermann J, Körner I, Daemen K, Clark EA, Aicher A, Pezzutto A.

J Biol Chem. 2001 Dec 7;276(49):45686-93. Epub 2001 Sep 24.

15.

ICOS ligand costimulation is required for T-cell encephalitogenicity.

Sporici RA, Beswick RL, von Allmen C, Rumbley CA, Hayden-Ledbetter M, Ledbetter JA, Perrin PJ.

Clin Immunol. 2001 Sep;100(3):277-88.

PMID:
11513541
16.

Monoclonal antibodies raised to human cells--specificity for pig leukocytes.

Haverson K, Bailey M, Stokes CR, Simon A, LeFlufy L, Banfield G, Chen Z, Hollemweguer E, Ledbetter JA.

Vet Immunol Immunopathol. 2001 Jul 20;80(1-2):175-86.

PMID:
11445227
17.

Summary of the first round analyses of the Third International Workshop on Swine Leukocyte Differentiation Antigens.

Haverson K, Saalmüller A, Chen Z, Huang CA, Simon A, Seebach J, Boersma WJ, Zwart R, Niewold TA, Thacker E, Llanes D, de la Lastra JM, Engelhardt H, Ezquerra A, Alonso F, Dominguez J, Ledbetter JA, Grosmaire L, Lee R, Nielsen J, Salmon H, Valpotic I, Sver L, Lackovic G, Summerfield A, Khanna KV.

Vet Immunol Immunopathol. 2001 Jul 20;80(1-2):25-34.

PMID:
11445216
18.

Overview of the Third International Workshop on Swine Leukocyte Differentiation Antigens.

Haverson K, Saalmüller A, Alvarez B, Alonso F, Bailey M, Bianchi AT, Boersma WJ, Chen Z, Davis WC, Dominguez J, Engelhardt H, Ezquerra A, Grosmaire LS, Hamilton MJ, Hollemweguer E, Huang CA, Khanna KV, Kuebart G, Lackovic G, Ledbetter JA, Lee R, Llanes D, Lunney JK, McCullough KC, Molitor T, Nielsen J, Niewold TA, Pescovitz MD, de la Lastra JM, Rehakova Z, Salmon H, Schnitzlein WM, Seebach J, Simon A, Sinkora J, Sinkora M, Stokes CR, Summerfield A, Sver L, Thacker E, Valpotic I, Yang H, Zuckermann FA, Zwart R.

Vet Immunol Immunopathol. 2001 Jul 20;80(1-2):5-23.

PMID:
11445215
19.

CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer.

Hellstrom I, Ledbetter JA, Scholler N, Yang Y, Ye Z, Goodman G, Pullman J, Hayden-Ledbetter M, Hellstrom KE.

Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6783-8. Epub 2001 May 22.

20.

CD83 is an I-type lectin adhesion receptor that binds monocytes and a subset of activated CD8+ T cells [corrected].

Scholler N, Hayden-Ledbetter M, Hellström KE, Hellström I, Ledbetter JA.

J Immunol. 2001 Mar 15;166(6):3865-72. Erratum in: J Immunol. 2009 Feb 1;182(3):1772-3.

21.

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Shan D, Ledbetter JA, Press OW.

Cancer Immunol Immunother. 2000 Mar;48(12):673-83.

PMID:
10752475
22.

A D-amino acid peptide inhibitor of NF-kappa B nuclear localization is efficacious in models of inflammatory disease.

Fujihara SM, Cleaveland JS, Grosmaire LS, Berry KK, Kennedy KA, Blake JJ, Loy J, Rankin BM, Ledbetter JA, Nadler SG.

J Immunol. 2000 Jul 15;165(2):1004-12.

23.

Characterization of human inducible costimulator ligand expression and function.

Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, Magaletti D, Buckwalter S, Ledbetter JA, Clark EA.

J Immunol. 2000 May 1;164(9):4689-96.

24.

IL-2 and IL-15 regulate CD154 expression on activated CD4 T cells.

Skov S, Bonyhadi M, Odum N, Ledbetter JA.

J Immunol. 2000 Apr 1;164(7):3500-5.

25.

Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF.

Zhao L, Rai SK, Grosmaire LS, Ledbetter JA, Fell HP.

J Hematother Stem Cell Res. 1999 Aug;8(4):393-9.

PMID:
10634177
26.

Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.

Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA.

J Immunol. 1999 Jun 1;162(11):6589-95.

27.

Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.

Connelly RJ, Hayden MS, Scholler JK, Tsu TT, Dupont B, Ledbetter JA, Kanner SB.

Int Immunol. 1998 Dec;10(12):1863-72.

PMID:
9885907
28.

A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome.

Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ.

Br J Haematol. 1998 Oct;103(1):176-88.

PMID:
9792306
29.

A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.

Bikah G, Lynd FM, Aruffo AA, Ledbetter JA, Bondada S.

Int Immunol. 1998 Aug;10(8):1185-96.

PMID:
9723705
30.

Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

Shan D, Ledbetter JA, Press OW.

Blood. 1998 Mar 1;91(5):1644-52.

31.

HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand.

Lee JW, Gersuk GM, Kiener PA, Beckham C, Ledbetter JA, Deeg HJ.

J Immunol. 1997 Oct 1;159(7):3211-9.

PMID:
9317119
32.

Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation.

Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC.

J Immunol. 1997 Aug 15;159(4):1594-8.

PMID:
9257817
33.

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.

Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A, Mittler RS.

J Exp Med. 1997 Jul 7;186(1):47-55.

34.

In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.

Francisco JA, Schreiber GJ, Comereski CR, Mezza LE, Warner GL, Davidson TJ, Ledbetter JA, Siegall CB.

Blood. 1997 Jun 15;89(12):4493-500.

35.

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L.

Nat Med. 1997 Jun;3(6):682-5.

PMID:
9176498
36.

Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. Redox independent activation of NF-kappaB.

Krejsa CM, Nadler SG, Esselstyn JM, Kavanagh TJ, Ledbetter JA, Schieven GL.

J Biol Chem. 1997 Apr 25;272(17):11541-9.

37.

Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages.

Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC.

J Exp Med. 1997 Apr 21;185(8):1511-6.

38.

Identification of amino acid residues important for ligand binding to Fas.

Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA.

J Exp Med. 1997 Apr 21;185(8):1487-92.

39.

Antibody engineering.

Hayden MS, Gilliland LK, Ledbetter JA.

Curr Opin Immunol. 1997 Apr;9(2):201-12. Review.

PMID:
9099794
41.

Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5.

Ledbetter JA, Francisco JA, Siegall CB, Gilliland LK, Hollenbaugh D, Aruffo A, Siadak AW, Mischel-Petty N, Grosmaire LS, Gordon ML, Brown TJ, Moran-Davis P, Mittler RS, Kiener PA, Nadler SG.

Crit Rev Immunol. 1997;17(5-6):427-35. Review.

PMID:
9419430
42.

Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation.

Sherbina NV, Linsley PS, Myrdal S, Grosmaire LS, Ledbetter JA, Schieven GL.

J Immunol. 1996 Nov 15;157(10):4390-8.

PMID:
8906814
43.

Surface expression of CD28 single chain Fv for costimulation by tumor cells.

Winberg G, Grosmaire LS, Klussman K, Hayden MS, Fell HP, Ledbetter JA, Mittler RS.

Immunol Rev. 1996 Oct;153:209-23. Review. No abstract available.

PMID:
9010725
44.

Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen.

Hayden MS, Grosmaire LS, Norris NA, Gilliland LK, Winberg G, Tritschler D, Tsu TT, Linsley PS, Mittler RS, Senter PD, Fell HP, Ledbetter JA.

Tissue Antigens. 1996 Oct;48(4 Pt 1):242-54.

PMID:
8946677
46.

Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin.

Francisco JA, Kiener PA, Moran-Davis P, Ledbetter JA, Siegall CB.

J Immunol. 1996 Aug 15;157(4):1652-8.

PMID:
8759752
47.

Apoptosis following interleukin-2 withdrawal from T cells: evidence for a regulatory role of CD18 (beta 2-integrin) molecules.

Röpke C, Gladstone P, Nielsen M, Borregaard N, Ledbetter JA, Svejgaard A, Odum N.

Tissue Antigens. 1996 Aug;48(2):127-35.

PMID:
8883302
48.
49.

The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation.

Inobe M, Aoki N, Linsley PS, Ledbetter JA, Abe R, Murakami M, Uede T.

J Immunol. 1996 Jul 15;157(2):582-8.

PMID:
8752905
50.

CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis.

Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E.

Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2499-504.

Supplemental Content

Loading ...
Support Center